Kolumnen und Serien
Beiträge zum Schlagwort:
PACIFIC: Quality of Life is maintained in NSCLC patients treated with durvalumab
In the randomised, double-blind phase III trial PACIFIC, durvalumab has shown to improve PFS while upholding quality of life measures.
CheckMate 032: Efficacy of nivolumab is enhanced in SCLC patients with high TMB with or without Ipilimumab
New research showed that among SCLC patients, the efficacy of using nivolumab was enhanced among those with a high TMB.
Early predictive biomarkers could identify non-responders to PD-1/PD-L1-Inhibitors
Changes in LDH above the upper limit of normal values at cycle 2 and in NLR ≥ 5 at 6 weeks predicts for disease progression.
The role of immunotherapy for patients with rare mutations
The role of immunotherapy for patients with uncommon EGFR mutations, ROS1 and C-MET who express PD-L1 is still unclear.
Nivolumab more active in lymph nodes
Immunotherapy has differential effects at different organ sites of metastases. Nivolumab treatment appeared to be more active in immune cells (IC) rich organs.
Peripheral Blood Biomarkers Associated with Clinical Outcome in NSCLC
Low/high absolute neutrophil count and high absolute eosinophil count was associated with a better outcome of nivolumab treatment.
Interferon-Gamma a more accurate biomarker than PD-L1?
Interferon-Gamma (IFNG) production by T-cells play a critical role in anti-cancer immune responses, a study shows.
PD-L1 Expression as a Biomarker of PD-1 Blockade in Advanced NSCLC
There is a positive correlation between increasing cutpoints of PD-L1 expression and ORR and 1yr PFS, but little correlation with 1yr OS.
PD-L1 expression associated with poor prognosis in lung SCC
The 1% cut-off value for PD-L1 might become a predictive marker, expression of PD-L1 might give negative prognostics.
Neoadjuvant Chemotherapy affects PD-L1-expression
The expression of PD-L1 was up-regulated after neo-adjuvant chemotherapy when using 5%, 10%, 20% expression threshold.